NEJM January 8, 2026 RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults

This research study evaluates the impact of a specific bivalent vaccine on reducing severe illness from respiratory syncytial virus (RSV) among individuals aged 60 and older. By comparing a large group of vaccinated seniors against an unvaccinated control group during a winter season, researchers discovered that the immunization offered significant protection against serious complications. The data specifically highlights that the vaccine was highly effective at preventing hospitalizations linked to both general and lower respiratory infections caused by the virus. Ultimately, the findings suggest that this medical intervention is a safe and successfultool for decreasing the burden of RSV-related hospital stays in the elderly population.